Research that was carried out by Baylor College of Medicine and Texas Children’s Hospital doctors has led to the U.S. Food and Drug Administration (FDA) granting Orphan Drug Designation to a treatment for developmental and epileptic encephalopathy (DEE) due to syntaxin-binding protein 1 (STXBP1) mutations.
This article was originally published on MedicalXpress.com